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Abstract  
A new synthetic methodology for preparing amide conjugates of the DO3A-N-(α-
amino)propionate chelator is disclosed in this manuscript. The synthesis of the DO3A-
N-(α-benzoylamido)propionate chelator is described as an illustrative example. The 
model Gd(DO3A-N-(α-benzoylamido)propionate) chelate displays accelerated water 
exchange, stability in a wide pH range and inertness towards transmetallation by Zn2+.  
The Gd(DO3A-N-(α-benzoylamido)propionate) complex is mainly excreted via the 
kidneys, producing a significant increase of the kidney medulla/cortex enhancement 
ratio in MR images of Wistar rats, reflecting probably its increased hydrophobicity 
compared to Gd(DTPA). The results suggest that Gd(DO3A-N-(α-amido)propionate) 
chelates are valuable leads for preparing safe high relaxivity MRI contrast agents. 
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Introduction 
Since its introduction 20 years ago, MRI has evolved into the leading imaging 
modality both in the clinics and in biomedical sciences (1). Constant developments in 
instrumentation, particularly the use of increasingly higher magnetic fields, and the use 
of contrast agents (CAs), have driven MRI to the forefront of medical imaging (2). Gd3+ 
chelates are the most useful CAs for MRI due to the high paramagnetism (7 unpaired 
electrons) and long electronic relaxation times of the Gd3+ ion (3). To ensure safety, 
Gd3+ ions are used as complexes with poly(aminocarboxylate) ligands, which prevents 
the inherent toxicity of the free metal ion and modulates its unfavorable 
pharmacokinetic behaviour. The efficacy of a CA is measured by its relaxivity (r1, r2)- 
the enhancement of the relaxation rate of the water protons brought about by a 1 mM 
concentration of Gd3+ (4,5). Increasing detection sensitivity, by maximizing relaxivity, 
has been the driving force in the development of new CAs (6). Nonetheless, the high 
relaxivities predicted theoretically haven’t yet been achieved in spite of the tremendous 
efforts and developments in the field (7). The main approaches to enhance detection 
sensitivity involve optimizing the relaxivity of individual chelates, eg. through 
clustering a high number of (high relaxivity) chelates into (bio)macromolecular carriers 
or self-assembly of monomeric chelates into supramolecular structures, and directing 
chelate constructs to the sites of interest by attaching targeting moieties recognized 
specifically by cellular receptors (6,8). All these approaches require chemical 
modification of the basic chelator structure in order to introduce “handles” for chemical 
functionalization.        
A few years ago, the discovery of severe toxicity associated with repeated CA 
MRI in individuals suffering from kidney function impairment shaded doubts about the 
safety of MRI CAs (9). This condition, named Nefrogenic Systemic Fibrosis (NSF), due 
to generalized formation of fibrotic (scarring) plates in the skin and internal organs, was 
correlated with the use of Gd3+ chelates of DTPA bis-amide chelators (10). Release of 
Gd3+ ions in vivo, due to insufficient kinetic and thermodynamic stability of the 
Gd(DTPA-bis-amide) chelates, seems the most likely reason for CA toxicity (11,12). 
Importantly, no cases have been associated with CAs of the DOTA family, even in 
patients suffering from kidney disease (12). The much higher kinetic and 
thermodynamic stability of the macrocyclic DOTA-type CAs precludes the release of 
Gd3+ ions in vivo. The adoption of stricter guidelines concerning the use of Gd3+-based 
CA has drastically reduced the number of NSF cases reported (13). Nonetheless, safety, 
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associated with chelate stability, rather than high relaxivity (high detection sensitivity), 
is becoming the new paradigm in CA MRI, which favours the use of macrocyclic, 
DOTA-type CAs. There are several CAs of this type approved for clinical use in 
Europe, most of which are extracellular CAs. Gd(HPDO3A) (Prohance®) has become 
the CA of choice in the clinical setting (14). Improving the performance of DOTA-type 
CAs (targeting, multimerization, responsiveness, etc.) requires chemical elaboration of 
the basic DOTA scaffold to allow conjugation to (bio)molecules. Endowing DOTA 
chelators with conjugability without compromising stability is a core problem in CA 
research. In fact, the most convenient route for chemical functionalization of the DOTA 
skeleton, differentiating an acetate arm for amide coupling, reduces the thermodynamic 
and kinetic inertness of Gd(DOTA-monoamide)-type chelates (15). Furthermore, 
neutral Gd(DOTA-monoamide)-type chelates display much slower water exchange, 
limiting the relaxivities potentially achievable by chelates displaying optimized 
rotational correlation times (τR). Introducing pendant functional groups on the 
ethylenediamine bridges on the DOTA skeleton is an effective, although costly solution 
(16). It is preferable from the synthetic point of view to elaborate the (pre-formed) 
available cyclen skeleton than starting chelator synthesis from scratch. We have recently 
reported the synthesis of a new chelator, DO3A-N-(α-amino)propionate (L1, Scheme 1) 
and the relaxometric characterization of its Gd3+ complex. The α-amino substituted 
propionate arm presumably imposes steric compression around the water binding site on 
the complex, resulting in an accelerated water exchange rate kex (17). The kex value for 
the Gd(DO3A-N-(α-amino)propionate) (GdL1) chelate is of the same order of 
magnitude as that reported for its (unsubstituted) propionate analogue Gd(DOTA-N-
propionate)- in the range considered ideal for attaining high relativities at 
intermediate/high field (15,18). Moreover, the GdL1 complex is stable in the pH range 
2-10 and inert towards transmetallation with Zn2+. The pendant available amine group is 
ideal for conjugation through a variety of ligation chemistries. However, an important 
issue remains to be addressed: what is the effect of amide conjugation on the stability 
and water exchange rate of Gd(DO3A-N-(α-amido)propionate) chelates? In this 
manuscript we describe an expeditious methodology for the synthesis of amide 
conjugates of the DO3A-N-(α-amino)propionate chelator. The relaxometric 
characterization and in vivo MRI evaluation of a model amide chelate, Gd(DO3A-N-(α-
benzoylamido)propionate) (GdL1), is reported.   
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Results and Discussion 
Synthesis  
Allying stability to conjugability is an important requisite for developing metal 
chelates into imaging and/or therapeutic agents. We have proposed before that the 
pendant amine group on the α-aminopropionate arm on the DO3A-N-α-
aminopropionate chelator is an ideal handle for conjugation to (bio)molecules (17). 
Fully deprotected LnL2 chelates (Scheme 1) could be used directly for conjugation (19). 
However, solubility issues and difficult manipulations and purifications can be avoided, 
especially with radio-labelled metal chelates, by labelling pre-formed fully deprotected 
conjugates. Scheme 1 discloses a new expeditious strategy for the synthesis of amide 
conjugates of the DO3A-N-(α-amino)propionate scaffold. 
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Scheme 1. Synthetic sequence for preparing the DO3A-N-(α-benzoylamido)propionate ligand 
and its Gd3+ chelate. a) K2CO3, MeCN; b) i. TFA/DCM, ii. K2CO3/ethylbromoacetate, MeCN; c) 
i. Dowex 1X2100-OH- resin, ii. Elution with hydrochloric acid 0.1 M; d) GdCl3.xH2O.    
 
 
Introducing a pre-formed Boc-dehydroamide (Ph, Boc)-Δ-AlaOMe 2 into the 
cyclen scaffold via Michael addition is the key step in this reaction sequence. Building 
up on our previous experience on the synthesis of bifunctional chelator 8 we envisaged 
that (Boc, amide)-dehydroalanines of type 2 could fulfil electronic and steric 
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requirements to perform well as electrophiles in Michael addition to cyclen. (Boc, 
amide)-dehydrolalanines of type 2 can be readily prepared in two steps from serine 
methyl ester hydrochloride 1 and stored at room temperature for extended periods (20). 
Michael addition of block (2) to cyclen 3 proceeded smoothly in acetonitrile, using 
K2CO3 as base, in 2-3 hours. An excess of cyclen, 1.5 eq., was used in order to bias the 
statistical mixture towards the monoalkylated product 4. Removing the Boc group at the 
monoalkylated intermediate 4 stage could avert retro-elimination during the next 
alkylation step. In fact, one pot treatment of 4 with TFA, followed by alkylation with 
ethyl bromoacetate in the presence of a large excess of K2CO3 produced the fully 
alkylated amide 5 in moderate yield without evidence of retro-elimination. One step 
deprotection of the fully alkylated pro-chelator 5 with  the ion-exchange resin Dowex 
1X2 OH- followed by elution with hydrochloric acid yielded the fully deprotected 
DO3A-N-(α-benzoylamido)propionate chelator 6 in overall non-optimised yield of 16% 
over 3 steps. Importantly, this approach is general, applicable to Boc-dehydroamides of 
type 2 lacking acid sensitive moieties or acid sensitive protecting groups on the amide 
moiety. 
 
Solution NMR and relaxometric studies 
As discussed above, the aim of this work is to ascertain if Gd3+ chelates of amide 
conjugates of the DO3A-N-(α-amino)propionate metal chelator retain the high stability, 
inertness and fast water exchange of its parent GdL2 complex. The soluble, low 
molecular weight Gd3+ chelate 7 (Scheme 1) was selected as a model system in order to 
avoid solubility and self-assembly complicating issues.     
 1H NMR spectra (600 MHz) of LnL1 complexes (Ln3+= La, Sm and Eu) at 298 K 
and neutral pH were found to contain very broad resonances for the macrocyclic and 
pendant arm methylene protons (data not shown), indicating the presence of an internal 
isomerisation process at intermediate exchange on the NMR time scale (21). The 
spectra of the parent LnL2 complexes are sharp in the same conditions (17). 
The water exchange rate, kex298, for the GdL1 complex was determined from 
variable-temperature 17O NMR studies (Figure 1 a-b). Additionally, the magnetic field 
dependence of the longitudinal water proton relaxivities (r1) was measured by 1H 
nuclear magnetic relaxation dispersion (NMRD) at 298 and 310 K (Figure 1c) with the 
objective of determining the parameters that describe water exchange and rotational 
dynamics for the GdL1 complex. 
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Figure 1. Temperature dependence of the (a) reduced transverse and longitudinal 17O 
relaxation rates 1/T2r and 1/T1r, and (b) chemical shifts Δωr; B = 9.4 T (ln(1/T1r), (■), 
(ln(1/T2r), (p)), and (c) NMRD profiles (298 K (p) and 310 K (■) for the Gd(DO3A-
N-(α-benzoylamido)propionate) complex.   
 
The Solomon-Blombergen-Morgan theory was used for analyzing simultaneously the 
experimental 1H NMRD data, as well as the 17O NMR reduced longitudinal (1/T1r) and 
transverse (1/T2r) relaxation rates and chemical shifts (Δωr) (5). In the analysis, the 
following parameters have been fitted: rate (kex298), activation enthalpy (ΔH‡) and 
	   8	  
activation entropy (ΔS‡) of the water exchange, the rotational correlation time (τRH298) 
and its activation energy (ER), the electron spin relaxation parameters (τV298, Δ2 and EV) 
and the scalar coupling constant (A/ħ). The diffusion constant and its activation energy 
have been fixed to DGdH298 = 26 x 10-10 m2s-1 and EDGdH298 = 22 kJ/mol, respectively. 
The Gd-water proton distance was fixed to rGdH = 3.1 Å, and the distance of closest 
approach between the Gd3+ ion and the outer sphere protons to aGdH = 3.6 Å (17,18,22). 
The parameters obtained from the simultaneous fitting of the data are shown on Table 1, 
and the corresponding fitted curves are shown in Figure 1. 
 
Table 1. Best fit parameters obtained for the Gd(DO3A-N-(α-
benzoylamido)propionate) chelate  from the simultaneous fitting of 
the NMRD data, 17O NMR longitudinal (1/T1r) and transverse 
(1/T2r) relaxation rates and chemical shifts (Δωr).  
 
 
 
 
 
 
 
 
 
 
  
           
In the fitting, one inner sphere water molecule was assumed in analogy with the 
parent GdL2 complex (17). This assumption was confirmed by the value obtained for 
the parameter A/ħ, characteristic of q = 1 complexes of the DOTA family. The rate 
constant for water exchange for the GdL1 complex (kex298 = (5.14 ±0.4) x 107 s-1) is of 
the same order of magnitude as that reported for its parent GdL2 complex (kex298 = 
(4±0.4) x 107 s-1) (17) and for the unsubstituted Gd(DOTA-N-propionate) complex 
(kex298 = 6.1 x 107 s-1) (15). Moreover, kex is around one order of magnitude higher than 
that reported for Gd(DOTA) (22). This result confirms our working hypothesis, that 
Gd3+ chelates of amide conjugates of the DO3A-N-(α-amino)propionate chelator retain 
the fast water exchange displayed by its parent GdL2 complex. This is an important 
Parameters GdL1a GdL2b Gd(DOTA)c 
q(H2O)  1 1 1 
ΔH‡[J/K/mol] 17±1.1 19.1 54.5 
ΔS‡[kJ/mol] -40±6 -35 +65 
kex298 [107 s-1] 5.14 ± 0.4 4 0.46 
ER [kJ/mol] 26.2±1.1 17 20 
τRH298[ps] 182±10 71 100 
EV [kJ/mol]  4.8±0.5 1 8.6 
τV298 [ps] 7.2±1.5 11 0.65 
Δ2 [1020 s-2] 0.5±0.06 0.25 - 
A/ħ [106 rad/s] -3.13±0.4 -3.6 -4.0 
  aParameters underlined have been fixed. bFrom ref.(17). c From ref.(22). 
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result, indicating that amide conjugates displaying an optimized rotational correlation 
time, τR, could attain high relaxivities at intermediate fields, as the water exchange rate 
is in the ideal range. The value for the rotational correlation time obtained from the 1H 
longitudinal relaxation rates (τRH298 = 182 ps) is characteristic of low molecular weight 
chelates, indicating that the complex does not self-assemble in the concentration range 
studied. At high magnetic fields, the relaxivity is dominated by fast rotation in solution, 
as demonstrated by the temperature dependence of the relaxivity.  
Complex stability is of paramount importance for meaningful biological 
applications. The NSF condition results, probably, from complex dissociation in the 
challenging biological medium. It is widely accepted that transmetallation with 
endogenous metal ions, the most abundant of which in blood serum is Zn2+, and ligand 
protonation assisted demetallation, at low pH, are the most likely mechanisms for Gd3+ 
leakage(23). The kinetic inertness of the GdL1 complex was evaluated using the 
transmetallation assay developed by Muller and co-workers (24), in which complex 
transmetallation by Zn2+ was studied in phosphate-buffer (10 mM, pH 7.1) (Figure 2).  
 
Figure 2. Evolution of the relative water proton paramagnetic relaxation rate 
R1p(t)/R1p(0) (20 MHz, pH 7.1, 298 K) versus time for a 1.5 mM solution of Gd(DO3A-
N-(α-benzoylamido)propionate complex in phosphate buffer (10 mM, pH 7.1) (○) and 
in phosphate buffer containing an equimolar amount of Zn2+ ions (●).  
 
Replacement of Zn2+ by Gd3+ in the initial complex would generate a time-
dependent decrease of the paramagnetic contribution to the water proton spin-lattice 
relaxation rate (R1p) due to precipitation of GdPO4. The time evolution of the relative 
water proton paramagnetic relaxation rate R1p(t)/R1p(0) versus time for the GdL1 
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complex in phosphate buffer, in the absence and in the presence of Zn2+ (Figure 2) 
surpasses  the accepted empirical criteria for kinetic stability and thermodynamic 
stability (24). Furthermore, the independence of the paramagnetic relaxation rates for 
the GdL1 complex from the solution pH (Figure 3) confirms that the complex is stable 
in the wide pH range 2-11. 
 
 
Figure 3. pH dependence of the relative water proton paramagnetic relaxation rate R1p 
(20 MHz, 25 ºC) for a 1.5 mM solution of Gd(DO3A-N-(α-benzoylamido)propionate. 
 
The interaction of the GdL1 complex with human serum albumin (HSA) was 
studied by relaxometric titration (Fig. S1, Supplementary Information). A very weak 
binding was detected, which is not likely to affect the pharmacokinetic behaviour of the 
complex in vivo.   
 
MRI Studies  
The GdL1 contrast agent was well tolerated by the rats. Their body temperature 
remained stable and no alteration on the body functions was observed during the course 
of the experiment.  
Series of T1-weighted spin-echo axial images of the DCE MRI experiments were 
obtained with the GdL1 complex (dose 0.1 mmol/kg body weight) and, for comparison 
purposes, with the Gd(DTPA) complex (dose 0.1 mmol/kg body weight). As can be 
seen (Figure 4A and B), both complexes follow mainly renal elimination with a very 
small hepatobiliary contribution to excretion.  
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Figure 4. Representative coronal T1-weighted spin echo MR images of a Wistar rat before and 
after injection of the contrast agents (A) GdL1, (B) Gd(DTPA) (dose 0.1 mmol kg-1 BW). 
 
The features of the data in Figure 4 are better understood as illustrated in Figure 5, 
which shows their quantitative analysis. Each time point corresponds to the average 
intensity within ROIs placed on the different organs. In order to compare the results for 
all the animals under study (n = 4), the data were normalized by calculating the mean 
relative enhancement of each ROI. Muscle and liver enhancement is comparably low 
with both complexes. The relative enhancement obtained with GdL1 increased almost 
immediately after intravenous injection from 0 up to about 250% in the kidney medulla 
and 200% in the kidney cortex, followed by a first order-like decrease to values around 
120% and 80%, respectively, after 50 minutes. The time course of the average relative 
enhancement after injection of Gd(DTPA) (Figure 5B) is in good agreement with the 
literature (25). The renal pharmacokinetic behavior of Gd(DTPA) is significantly 
different from that observed for the GdL1 complex. Kidney cortex enhancement is 
much less abrupt than for GdL1, reaching a maximum of about 100% after 10 minutes 
post injection, followed by a steady decrease to a value (~80%) comparable to that 
reached by GdL1 after 50 minutes.  
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Figure 5. Time course of signal intensity, relative to the initial value (up to 50 min post-
injection) of several regions of interest during dynamic contrast enhancement MRI experiments 
in rats with (A) GdL1 (0.1 mmol kg-1 BW) and (B) Gd(DTPA) (0.1 mmol kg-1 BW). The time 
courses are data for mean values of four animals and the corresponding standard error. 
 
However, the main difference between Gd(DTPA) and GdL1 regards kidney medulla 
enhancement. While for the GdL1 complex there is a sharp increase just after injection, 
followed by a first order-like decrease, for Gd(DTPA) a saturation-like kinetic 
behaviour is observable. After 50 minutes, a significantly higher enhancement of the 
kidney medulla is attained with the Gd(DTPA) comparing to GdL1 complex (200% vs 
120%). As a consequence of the disparate pharmacokinetics, the ratio of medulla/cortex 
enhancement is approximately constant for the GdL1 complex over the duration of the 
experiment, while it increases significantly for the Gd(DTPA) complex. As both 
complexes share the same overall (-1) charge and plausibly a similar chelate geometry, 
the observed difference of pharmacokinetic behaviour is likely to be due to the 
increased hydrophobicity of the GdL1 complex. 
 
Conclusions  
 In this manuscript we demonstrate that Gd3+ complexes of amide conjugates of 
the DO3A-N-(α-amido)propionate chelator retain the fast water exchange and stability 
of their parent DO3A-N-(α-amino)propionate chelator. An expeditious, convergent 
synthetic methodology for DO3A-N-(α-amido)propionate chelators is illustrated by the 
synthesis of the model chelator DO3A-N-(α-benzoylamido)propionate. DCE-MRI 
studies in rats revealed that the Gd(DO3A-N-(α-benzoylamido)propionate) chelate is 
mainly excreted via the kidneys. A significant increase of the enhancement ratio kidney 
medulla/kidney cortex is produced by the contrast agent after 50 minutes, reflecting 
probably its increased hydrophobicity comparing to Gd(DTPA). 
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 The results presented here suggest that Gd(DO3A-N-(α-amido)propionate) 
chelates are valuable leads for preparing safe high relaxivity MRI CAs. In fact, 
Gd(DO3A-N-(α-amido)propionate) chelates with optimized water exchange features, 
when bound to suitable carriers, are likely to originate high relaxivities at intermediate 
fields by virtue of the simultaneous optimisation of kex and τR. The high relaxivities of 
such imaging platforms allied to the chelate stability and safety could find many uses in 
biomedical and pre-clinical diagnostic MRI applications.  
 
Experimental 
Materials and Methods 
Chemicals were purchased from Sigma-Aldrich and used without further 
purification. Solvents used were of reagent grade and purified by usual methods. Cyclen 
was purchase from CheMatech. Reactions were monitored by TLC on Kieselgel 60 
F254 (Merck) on aluminium support. Detection was by examination under UV light 
(254 nm) and by adsorption of iodine vapour. Flash chromatography was performed on 
Kieselgel 60 (Merck, mesh 230–400). The relevant fractions from flash chromatography 
were pooled and concentrated under reduced pressure, T < 313 K. Ion exchange 
chromatography was performed on Dowex1X2100-OH- resin (Sigma Aldrich). The 
resin was purchase as the Cl- form and converted to the OH- form by the standard 
procedure. 1H and 13C NMR spectra (assigned by 2D DQF-COSY and HMQC 
techniques) were run on a Varian Unity Plus 300 NMR spectrometer, operating at 
299.938 MHz and 75.428 MHz, for 1H and 13C, respectively. Chemical shifts (δ) are 
given in ppm relative to the CDCl3	   solvent (1H, δ 7.27; 13C, δ  77.36) as internal 
standard. For 1H and 13C spectra recorded in D2O, chemical shifts (δ) are given in ppm 
relative to TSP as internal reference (1H, δ  0.0) and tert-butanol as external reference 
(13C, CH3 δ  30.29).  
 
Synthesis of monoalkylated cyclen (4): K2CO3 (4.07 g, 29.46 mmol) was added to a 
solution of cyclen (1.27 g, 7.37 mmol) in MeCN (50 cm3). To this solution was added 
(Ph, Boc)-Δ-AlaOMe 2 (1.5 g, 4.91 mmol). The suspension was stirred vigorously at 
room temperature for 3 hrs. The suspension filtered and the filtrate was evaporated 
under reduced pressure. The residue was purified by flash chromatography (100% 
CH2Cl2 à CH2Cl2/EtOH/NH3/H2O (50:50:1:1)) to afford compound 4 as a viscous light 
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yellow oil (1.34 g, 59.1%). 1H NMR (300 MHz, CDCl3): δ = 1.47 (s, 9H, Boc), 2.50-
2.90 (m, 16H, N(CH2)2N), 3.01 (dd, J= 14.1 and 6 Hz, 1 H, NCHaHbCH), 3.49 (dd, J= 
14.4 and 5.1 Hz, 1 H, NCHaHbCH), 3.76 (s, 3H, OMe), 5.25 (t, J= 6 and 5.1 Hz, 1H, 
NCHaHbCH), 7.30-7.70 (5H, m, Ar). 13C NMR (75.4 MHz, CDCl3): δ= 27.27 
(C(CH3)3), 44.77 (CH2), 45.83 (CH2), 46.70 (CH2), 51.27 (CH2), 52.51 (OCH3), 55.61 
(NCH2CH), 56.08 (CH), 83.88 (C(CH3)3), 127.87 (Ar), 127.96 (Ar), 131.27 (Ar), 
137.02 (Ar), 152.72 (NC(O)O), 170.57 (C(O)Ar), 172.62 (C(O)OCH3). HRMS (ESI): 
m/z: cacd for C24H39N5O5: 478.3029, found: 478.3024. 
 
Synthesis of tetraalkylated cyclen (5):A solution of monoalkylated cyclen 4 (1.30 g, 
2.72 mmol) in trifluoroacetic acid in dichlorometane (60%, 25 cm3) was stirred 
overnight at room temperature. The solvent was evaporated at reduced pressure and the 
residue was redissolved in dichloromethane. The solvent was evaporated, and this 
procedure was repeated several times to give a light yellow thick oil. 1H NMR 
spectroscopy (CDCl3) revealed the disappearance of the signals assigned to the Boc 
groups in the precursor compound 4. The deprotection was assumed as quantitative. To 
a solution of Boc-deprotected compound 4 (2.72 mmol, assuming quantitative 
deprotection) in MeCN (40 cm3) was added K2CO3 (4.51 g, 32.6 mmol). The 
suspension was vigorously stirred for 30 minutes at room temperature before adding 
ethyl bromoacetate (1.06 cm3, 9.52 mmol). The suspension was further stirred at room 
temperature for 2.5 hrs. The suspended solid was removed by filtration, the filtrate was 
evaporated under reduce pressure and the residue was purified by flash chromatography 
(100% CH2Cl2 à CH2Cl2/EtOH (1:1)) to afford compound 5 (0.632 g, 37%) as a white 
foam. 1H NMR (300 MHz, CDCl3): δ= 1.22 (m, 9 H, CH2CH3),  2.2-3.60 (broad, 
overlapped signals with a integration corresponding to, 24 H, NCH2 and NCHaHbCH), 
3.71 (s, 3H, C(O)OCH3), 5.14 (m (br), 1H, NCHaHbCH), 7.44-8.03 (5H, m, Ar). 13C 
NMR (75.4 MHz, CDCl3): selected signals: 13.95 (CH2CH3), 48.74 (CH),  49.04 (CH2), 
50.38 (CH2), 51.48 (CH2),  52.59 (CH2), 52.95 (OCH3), 53.62 (CH2CH), 53.62 (CH2), 
54.86 (CH2), 54.96 (CH2), 55.19 (CH2), 55.37 (CH2), 55.75 (CH2), 56.18 (CH2),  60.62 
(CH2), 60.94, 61.13, 61.21 (OCH2), 127,83 (Ar), 128,12 (Ar), 128,41 (Ar), 131,53 (Ar),  
131,84 (Ar), 132.62 (Ar), 167.79 (C(O)Ar), 170.29 (2X C(O)OCH2), 170.52 
(C(O)OCH3), 170.91 (C(O)OCH2). HRMS (ESI): m/z: cacd for C31H49N5O9: 636.3609, 
found: 636.3590. 
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Fully deprotected DO3A-N-(α-benzoylamido)aminopropionate metal chelator  (6): 
Compound 5 (0.566 g, 0.89 mmol) was dissolved in a mixture made up of 20 cm3 of 
water and 20 cm3 of ethanol. The solution was adjusted to pH ~ 10-11 by adding small 
portions of Dowex 1X2-100-OH- resin. The suspension was kept under stirring at room 
temperature for 2 hours. The wet resin was transferred into a chromatography column, 
washed with water (~50 cm3) and eluted with 0.1 M hydrochloric acid. The relevant 
fractions, identified by TLC (ethanol water 1/1, revelation with iodine vapor) were 
pooled, concentrated at room temperature and further dried under vacuum to afford the 
final deprotected compound, in the hydrochloride form,  as a light yellow solid (6) 
(0.276 g, 71.2%). 1H  NMR (300 MHz, CDCl3): δ= 2.9-3.6 (broad, overlapped signals 
with a integration corresponding to, 18 H, N(CH2)2N and NCHaHbCH), 3.81 (broad, 
overlapped signals with a integration corresponding to, 6 H, NCH2), 4.80 (m (br), 1H, 
CH), 7.53-7.88 (5H, m, Ar). 13C NMR (75.4 MHz, CDCl3): selected signals: 43.02 
(CH2), 48.11 (CH2), 48.93 (CH2), 49.03 (CH2), 49.78 (CH2), 51.39 (CH2),  51.71 (CH), 
51.91 (CH2), 54.53 (CH2), 56.08 (CH2), 56.77 (2x CH2), 127,46 (2x Ar), 129,04 (2x 
Ar), 132,60 (Ar), 133.32 (Ar), 170.20 (C(O)), 177.17 (C(O)Ar). HRMS (ESI): m/z: 
cacd for C24H36N5O9: 538,2513, found: 538.2508. 
 
1H and 17O NMR and 1H NMRD experiments  
Sample preparation 
To an aqueous solution of the ligand (pH = 5.0) was added drop-wise an aqueous 
solution of the corresponding LnCl3.xH2O in a 1:1 mole ratio. The solution was stirred 
at room temperature over 1 hour while keeping its pH at around 5.7 by adding aqueous 
KOH. The solution was concentrated under reduced pressure to afford off white solids. 
The solutions for NMR measurements were obtained by dissolution of the appropriate 
amounts of solid complexes in D2O (V = 1 cm3) to obtain 20 mM concentrations. 
Proton 1D spectra of the solutions of the paramagnetic (Sm3+ and Eu3+) and diamagnetic 
(La3+) complexes were obtained at 298 K on a Varian VNMRS 600 (14.09 T, 600.14 
MHz) NMR spectrometer. 
The solutions of the GdL1 complex for 17O NMR and 1H NMRD experiments 
were prepared by mixing equimolar amounts of GdCl3 and ligand. A slight excess (5%) 
of ligand was used. The solution was adjusted to pH ~5.8 with aqueous NaOH and was 
allowed to react for 24 hours at room temperature. The absence of free metal was 
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checked in each sample by testing with xylenol orange (22,26,27). The pH of the stock 
solution was adjusted by adding aqueous NaOH (0.1 mM). 17O-enriched water (17O: 
11.4%) was added to the solutions for 17O measurements to improve sensitivity. The 
final concentration of the complex solution was 17.56 mmol kg-1 at pH = 6.90. For the 
NMRD experiments a 5.00 mM solution of complex at pH 6.98 was used.  
 
17O NMR experiments 
Variable-temperature 17O NMR measurements were performed on a Bruker 
Avance-500 (11.7 T) spectrometer. A BVT-3000 temperature control unit was used to 
stabilize the temperature, measured by a substitution technique. The samples were 
sealed in glass spheres that fitted into 10 mm o.d. NMR tubes, to eliminate 
susceptibility corrections to the chemical shifts (28). Longitudinal relaxation rates (1/T1) 
were obtained by the inversion recovery method, and transverse relaxation rates (1/T2) 
by the Carr-Purcell-Meiboom-Gill spin-echo technique. As an external reference, 
acidified water of pH 3.4 was used.  
 
NMRD measurements 
The measurements were performed by using a Stelar Spinmaster FFC NMR 
relaxometer (0.01–20 MHz) equipped with a VTC90 temperature control unit. At higher 
fields, the 1H relaxivity measurements were performed on a Bruker Electromagnet at the 
frequencies of 30 MHz, 40 MHz, 60 MHz and 80 MHz. In each case, the temperature 
was measured by a substitution technique. Variable temperature measurements were 
performed at 25 and 37◦C. 
 
Relaxivity studies of pH dependence and Zn2+ transmetallation  
The transmetallation reaction of GdL1 with Zn2+ was studied by the time 
dependent decrease of the water proton longitudinal relaxation rate, R1, measured on a 
Bruker Minispec mq20 (20 MHz, 298 K) relaxometer, of a phosphate-buffered saline 
solution (PBS, pH 7.1, 10 mM) containing 1.5 mM of GdL1 after adding an equimolar 
amount of ZnCl2, while the sample was vigorously stirred (29). The water longitudinal 
relaxation rate was also measured as a function of time on the PBS buffered solution 
(pH 7.1, 10 mM) containing 2.5 mM GdL1 (30). The pH dependence of the relaxivity of 
the GdL1 solution was also measured on the same relaxometer. 
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MRI experiments 
In vivo MRI studies. The experimental protocols performed were approved by the 
appropriate institutional review committees and meet the guidelines of their responsible 
governmental agency. The Magnetic Resonance Imaging (MRI) experiments were all 
performed on a Bruker Pharmascan platform (Bruker Medical Gmbh, Ettlingen, 
Germany) using a 7.0-T horizontal-bore superconducting magnet, equipped with a 1H 
selective 60 mm birdcage resonator and a Bruker gradient insert with 90 mm diameter 
(maximum intensity 360 mT/m). Data were acquired using a Hewlett-Packard console 
running Paravision software (Bruker Medical Gmbh, Ettlingen, Germany) under a 
LINUX environment.  
All MRI examinations were carried out on male Wistar rats (n = 4, 250-260 g 
body weight) anaesthetized initially by inhalation in an induction box with O2 (1 l/min) 
containing 3 % isoflurane, and maintained during the experiment using a mask and 1-2 
% isoflurane on O2. Animals were taped down into a holder, to minimize breathing-
related motion, and were then placed in a heated probe, which maintained the core body 
temperature at approx. 37 oC, monitored by a rectal probe. The physiological state of the 
animal was monitored throughout the entire experiment by a Biotrig physiological 
monitor (Bruker Medical Gmbh, Ettlingen, Germany), using the respiratory rate and 
body temperature. 100 mM solutions of Gd(DO3A-N-(α-benzoylamido)propionate and  
Gd(DTPA) (Magnevist®, Schering, Berlin, Germany) were prepared in distilled water 
and the pH was adjusted to 7.2. The solutions were injected into the catheterized tail 
vein as a bolus in 20 s (0.1 mmol Gd.kg-1 body weight) using an infusion pump (Panlab, 
Barcelona, Spain). Dynamic contrast-enhanced (DCE) MRI experiments were 
performed with series of T1-weighted spin echo images sequentially acquired over 1 h, 
following the injection of the contrast agent 10 min after the beginning of the study. The 
acquisition parameters were: TR = 310 ms, TE = 10.58 ms, number of averages = 2, ten 
coronal slices, slice thickness = 2 mm, FOV = 5.0 x 5.0 cm, matrix = 256 x 256, 30 
repetitions with a total acquision time of 119 s.  
 
MRI Data analysis. Data were analyzed with Image J (http://rsbweb.nih.gov/ij/). With 
the aim of comparing the pharmacokinetics obtained from different animals, the data 
were normalized by calculating the percentage of relative, rather than absolute, 
enhancement: 
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where I is the signal intensity at any given time after CA injection and I0 is the intensity 
before injection. Pharmacokinetic behaviour was analyzed by calculating the average 
enhancements within different ROIs placed on each one of the following regions: liver, 
kidney medulla, kidney cortex and muscle.  
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